Webinar Technology

Advancing precision medicine through multi-omics: An integrated approach to tumor profiling

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Advancing precision medicine through multi-omics: An integrated approach to tumor profiling

Recorded 16 September 2015

Speakers

Downloads

While technological breakthroughs of the last decade have greatly advanced our understanding of the cancer genome, they have also revealed the immense complexity and heterogeneity of tumors. The key to further advancing our understanding and treatment of cancer is to distinguish between genes and pathways that drive tumorigenesis (driver events) and neutral, passenger events. A growing body of evidence has shown that not all DNA-level alterations have biological implications, making it necessary to examine multiple ꞌomics levels including the transcriptome and proteome, to identify critical driver events. In this webinar, our expert panel will discuss how using a multi-omics–based approach to cancer research can advance our understanding of cancer biology as well as lead to the discovery of novel biomarkers.

During the webinar, the speakers will:

  • Discuss how analyzing multi-omics data, such as copy number alteration and coding and noncoding RNA expression, can lead to more rapid identification and prioritization of cancer driver events
  • Explain how advancements in technologies that are sensitive enough to detect all-important genetic and transcriptomic changes are driving the discovery of novel biomarkers
  • Present the advantages of examining multiple versus single analytes to explain diagnostic, prognostic, and predictive outcomes
  • Answer your questions live during the broadcast!

 The webinar will last approximately 60 minutes.

To learn more about products or technologies related to this webinar, 
go to: www.affymetrix.com/translational

Speaker bios

Giovanni Martinelli, M.D.

University of Bologna
Bologna, Italy

Following his medical studies at the University of Verona Medical School, Prof. Martinelli specialized in hematology and medical genetics at the University of Verona. From 1994 to 2005, he was a full-time medical doctor at the Institute of Hematology and Medical Oncology “L. & A. Seràgnoli” at the University of Bologna, where since 2005 he has held the position of Associate Professor. He is also head of the Laboratory of Molecular Biology at the Seràgnoli Institute. Prof. Martinelli’s main fields of research are acute leukemia, chronic myeloid leukemia, and the development of targeted therapies in the major hematological syndromes. He is widely published in peer-reviewed journals and a member of the American Society of Hematology, the American Society of Clinical Oncology, the European Hematology Association, the American Association for Cancer Research, the American Association for the Advancement of Science, the Società Italiana di Ematologia, and the Società Italiana di Ematologia Sperimentale.

Nicholas Foreman, M.B.Ch.B.

Children’s Hospital Colorado
Aurora, CO

Dr. Foreman, who held the Seebaum-Tschetter Chair of Pediatric Neuro-Oncology for the past 20 years, is the director of pediatric neuro-oncology at Children’s Hospital Colorado and a professor of pediatrics at University of Colorado Denver. He received his M.B.Ch.B from Sheffield University in England where he also completed a residency in pediatrics. Dr. Foreman followed his training with a fellowship in pediatric oncology at Royal Hospital for Sick Children in Bristol, England and a fellowship in pediatric hematology and oncology at St. Jude’s Children’s Research Hospital in Memphis, TN. Widely published in peer reviewed journals, Dr. Forman’s main interest lies in the development of clinical protocols with difficult to treat brain tumors. His lab concentrates on the development of novel glial tumor therapies, specifically those directed at ependymoma and glioblastoma, with a focus on immunobiology and outcome, gene expression analysis and correlation with novel therapeutics, prognostic factors, and high-dose therapy development.

Sean Sanders, Ph.D.

Science/AAAS
Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here